Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RB-601
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Radiance Biopharma
Deal Size : $1,165.0 million
Deal Type : Licensing Agreement
China-based Novatim Notches New Deal with Another US Biotech
Details : The agreement aims for the development and commercialization of RB-601 (KY-0301), a novel Antibody Drug Conjugate (ADC) comprising a Bispecific Nanobody targeting c-MET and EGFR.
Product Name : KY-0301
Product Type : Antibody-drug Conjugate
Upfront Cash : $15.0 million
September 03, 2025
Lead Product(s) : RB-601
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Radiance Biopharma
Deal Size : $1,165.0 million
Deal Type : Licensing Agreement
Reset All
